Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells

BACKGROUND: Dendritic cells (DCs) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness the key cDC1 subtype required for effective CD8(+) T-cell-mediated tumor immune responses. Vaccine immunogenicity could be enhanced by specific delivery of immunogenic tumor antigen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Masterman, Kelly-Anne, Haigh, Oscar L, Tullett, Kirsteen M, Leal-Rojas, Ingrid M, Walpole, Carina, Pearson, Frances E, Cebon, Jonathon, Schmidt, Christopher, O'Brien, Liam, Rosendahl, Nikita, Daraj, Ghazal, Caminschi, Irina, Gschweng, Eric H, Hollis, Roger P, Kohn, Donald B, Lahoud, Mireille H, Radford, Kristen J
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Clinical/Translational Cancer Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7394304/
https://ncbi.nlm.nih.gov/pubmed/32737142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000691
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars